Global Transdermal Drug Delivery System Market Growth (Status and Outlook) 2025-2031

The global Transdermal Drug Delivery System market size is predicted to grow from US$ 18880 million in 2025 to US$ 40990 million in 2031; it is expected to grow at a CAGR of 13.8% from 2025 to 2031.

Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.

Global Transdermal Drug Delivery System key players include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), etc. Global top five manufacturers hold a share over 65%. North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share over 45% percent.

In terms of product, Nitroglycerin is the largest segment, with a share over 25%. And in terms of application, the largest application is OTC, followed by RX.

LPI (LP Information)' newest research report, the “Transdermal Drug Delivery System Industry Forecast” looks at past sales and reviews total world Transdermal Drug Delivery System sales in 2024, providing a comprehensive analysis by region and market sector of projected Transdermal Drug Delivery System sales for 2025 through 2031. With Transdermal Drug Delivery System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transdermal Drug Delivery System industry.

This Insight Report provides a comprehensive analysis of the global Transdermal Drug Delivery System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Transdermal Drug Delivery System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transdermal Drug Delivery System market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transdermal Drug Delivery System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transdermal Drug Delivery System.

This report presents a comprehensive overview, market shares, and growth opportunities of Transdermal Drug Delivery System market by product type, application, key players and key regions and countries.

Segmentation by Type:
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other

Segmentation by Application:
OTC
Rx

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier

Please note: The report will take approximately 2 business days to prepare and deliver.